Lioresal Intrathecal (Baclofen)

Baclofen binds to GABA_B receptors on neurons in the spinal cord, reducing calcium entry into presynaptic terminals. This limits the release of excitatory neurotransmitters, dampening reflex pathways that cause involuntary muscle contraction. The result is a dose‑dependent relaxation of hypertonic muscles.

The exact infusion rate and total daily dose are individualized. A qualified prescriber determines the starting dose, titration schedule, and maintenance level based on the patient’s clinical response, severity of spasticity, and tolerance. No standard dosing information is provided in public product literature.

The safety of intrathecal baclofen in pregnant or nursing women has not been established. The product carries an unknown pregnancy category, and clinicians generally avoid use unless the therapeutic benefit outweighs potential risks to the fetus or infant. Breastfeeding considerations follow the same precautionary approach.

To request Lioresal Intrathecal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Intrathecal delivery of baclofen achieves higher spinal cord concentrations with lower systemic exposure than oral baclofen, often providing superior spasticity control and fewer systemic side effects. Compared with other oral agents such as tizanidine, intrathecal baclofen offers more consistent relief for severe, refractory spasticity but requires surgical implantation of a delivery pump.

Lioresal Intrathecal should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Do not freeze. Follow aseptic techniques when preparing the infusion set to maintain sterility.

The medication is delivered via a surgically implanted intrathecal pump that continuously infuses the baclofen solution into the cerebrospinal fluid through a catheter placed in the spinal canal. Administration is performed by trained healthcare professionals, and the pump’s rate can be programmed and adjusted according to the patient’s therapeutic response.

The most critical risks include respiratory depression, severe hypotension, and infection at the catheter or pump site, which can lead to meningitis or sepsis. Sudden withdrawal of baclofen, due to pump malfunction or catheter blockage, may cause life‑threatening hypertonic crises. Immediate medical attention is required if any of these events occur.

Patients with known hypersensitivity to baclofen or any component of the formulation should avoid the product. Individuals with uncontrolled severe cardiovascular disease, active infection at the implantation site, or those unable to undergo surgical implantation of the intrathecal pump are generally contraindicated. Clinical judgment determines suitability on a case‑by‑case basis.